دورية أكاديمية
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
| العنوان: | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. |
|---|---|
| المؤلفون: | Lenman JA, Turnbull MJ, Reid A, Fleming AM |
| المصدر: | Journal of the neurological sciences [J Neurol Sci] 1977 Jun; Vol. 32 (2), pp. 219-25. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375403 Publication Model: Print Cited Medium: Print ISSN: 0022-510X (Print) Linking ISSN: 0022510X NLM ISO Abbreviation: J Neurol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier, <19 -> |
| مواضيع طبية MeSH: | Amantadine/*therapeutic use , Homovanillic Acid/*urine , Hydroxyindoleacetic Acid/*urine , Levodopa/*therapeutic use , Methylhistamines/*urine , Movement Disorders/*urine , Phenylacetates/*urine, Chorea/drug therapy ; Chorea/urine ; Humans ; Middle Aged ; Parkinson Disease/drug therapy ; Parkinson Disease/urine ; Tremor/drug therapy ; Tremor/urine |
| مستخلص: | We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor. The effect of amantadine on urinary excretion has been measured in each group of patients as well as the effect of levodopa in patients with Parkinson's disease. In patients with Parkinson's disease, excretion of 1,4-MeHm and HVA was significantly lower than in controls. Patients with choreiform movements had a reduced excretion of HVA but trends toward low levels of 1,4-MeHm and, in patients with Huntington's chorea, elevated excretion of 5-HIAA, were not significant. In patients with essential tremor, urinary excretion of the amine metabolities studied did nof differ significantly from controls. Administration of amantadine to patients with Parkinson's disease was not followed by increased excretion of monoamine metabolites except in those patients who were already receiving anticholinergic drugs. This increase is not significant and there was no effect in other groups of patients. These findings lend no support to the view that amantadine has a general amine-releasing action although there is limited evidence for such an effect in Parkinson's disease. In addition to the expected increase in HVA excretion, administration of levodopa to Parkinsonian patients was followed by significantly reduced excretion of 1,4-MeHm and 5-HIAA. However, if amantadine and levodopa were given together, excretion of 5-HIAA was still reduced, but that of 1,4-MeHm was normal. Levodopa may thus modify the turnover of histamine, which appears to be reduced in Parkinson's disease, and this effect may be modified by amantadine. |
| المشرفين على المادة: | 0 (Methylhistamines) 0 (Phenylacetates) 46627O600J (Levodopa) 54-16-0 (Hydroxyindoleacetic Acid) BF4C9Z1J53 (Amantadine) X77S6GMS36 (Homovanillic Acid) |
| تواريخ الأحداث: | Date Created: 19770601 Date Completed: 19770825 Latest Revision: 20190724 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1016/0022-510x(77)90237-4 |
| PMID: | 874521 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0022-510X |
|---|---|
| DOI: | 10.1016/0022-510x(77)90237-4 |